Dashboard

Alnylam Pharmaceuticals, Inc.

ALNYNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$33B

Price$246.5152w $205.48 – $491.22

Conviction5/ 5

Revenue (TTM)$4.8B

Revenue growth YoY+95.1%

P/E (trailing)40.8

Gross margin79.7%

Operating margin20.8%

Net margin16.8%

52w price change-19.5%

Next earningsOct 29, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Sep 22
OtherSEC
SEC Form 4 insider transaction filing.
Jul 30
Financial resultsSEC
Filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
Jun 3
Ownership changeSEC
Form 4 filing reporting change in beneficial ownership by an insider at Alnylam Pharmaceuticals.
Jun 3
Ownership changeSEC
SEC Form 4 insider transaction filing
May 27
LeadershipSEC
8-K (items 5.02, 5.07) reports officer/director changes and shareholder vote results from 2026-05-20 meeting.
May 22
Ownership changeSEC
SEC Form 4 insider transaction filing.
May 22
Ownership changeSEC
SEC Form 4 filed reporting change in beneficial ownership.
May 22
Ownership changeSEC
SEC Form 4 insider transaction filing.
May 22
Ownership changeSEC
SEC Form 4 insider ownership change filing on 2026-05-22.
May 22
Ownership changeSEC
SEC Form 4 filing reporting change in beneficial ownership by insider.
May 22
Ownership changeSEC
SEC Form 4 insider ownership filing.
May 22
Ownership changeSEC
Form 4 insider ownership filing
May 22
Ownership changeSEC
SEC Form 4 insider transaction filing.
May 22
Ownership changeSEC
SEC Form 4 insider ownership filing.
May 14
Ownership changeSEC
Form 4 insider ownership change filing.

Not financial advice — research and opinion only. Disclosures